公开(公告)号：US20110129860A1

公开(公告)日：2011-06-02

申请号：US12783256

申请日：2010-05-19

申请人： Johann Karl ,  Norbert Wild ,  Ursula Garczarek

发明人： Johann Karl ,  Norbert Wild ,  Ursula Garczarek

IPC分类号： G01N33/68

CPC分类号： G01N33/57419 ,  G01N33/721 ,  G01N2333/4727 ,  G01N2333/805

摘要： The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention.

摘要翻译： 本发明涉及一种协助评估结肠直肠癌的方法。 该方法特别用于评估体外存在或不存在结肠直肠癌。 该方法例如通过分析生物化学标记来实施，包括在粪便样品中测量血红蛋白/触珠蛋白复合物和钙卫蛋白的浓度，并将确定的浓度与不存在或存在结肠直肠癌相关联。 为了进一步改进基于本发明方法的结肠直肠癌的评估，可以在粪便样品中与血红蛋白/触珠蛋白复合物和钙卫蛋白一起测定一种或多种另外的标记物的水平，并与结肠直肠癌的存在或不存在相关 。 本发明还涉及包含血红蛋白/触珠蛋白复合物和钙卫蛋白的标记物在早期诊断结肠直肠癌中的用途，并且其教导了用于实施本发明方法的试剂盒。

公开(公告)号：US20100240068A1

公开(公告)日：2010-09-23

申请号：US12791929

申请日：2010-06-02

申请人： Johann Karl ,  Herbert Andres ,  Ursula Garczarek ,  Wolfgang Rollinger ,  Norbert Wild

发明人： Johann Karl ,  Herbert Andres ,  Ursula Garczarek ,  Wolfgang Rollinger ,  Norbert Wild

IPC分类号： G01N33/573

CPC分类号： G01N33/57419

摘要： The present invention relates to a method for assessing colorectal cancer (CRC) in vitro including measuring in a sample the concentration and/or activity of a seprase polypeptide and/or fragments thereof and of either anti-p53 and/or osteopontin and/or ferritin, of optionally one or more other marker of CRC, and using the combined measurement result in the assessment of CRC. Furthermore, it especially relates to a method for assessing CRC from a liquid sample, derived from an individual by measuring seprase and at least anti-p53, ferritin and/or osteopontin in the sample. The method according to the present invention can, e.g., be used in the early detection of cancer by screening of asymptomatic individuals or in the surveillance of patients who undergo surgery.

摘要翻译： 本发明涉及体外评估结肠直肠癌（CRC）的方法，包括在样品中测量seprase多肽和/或其片段和抗p53和/或骨桥蛋白和/或铁蛋白的浓度和/或活性 ，可选地一个或多个CRC的其他标志物，并且使用组合的测量结果来评估CRC。 此外，它特别涉及通过测量样品中的seprase和至少抗p53，铁蛋白和/或骨桥蛋白来评估来自个体的液体样品的CRC的方法。 根据本发明的方法可以例如通过筛选无症状个体或在进行手术的患者的监视中用于癌症的早期检测。

公开(公告)号：US20100159479A1

公开(公告)日：2010-06-24

申请号：US12613760

申请日：2009-11-06

申请人： Wolfgang Rollinger ,  Johann Karl ,  Norbert Wild ,  Herbert Andres ,  Peter Heiss ,  Ursula Garczarek ,  Andrea Geistanger ,  Friedemann Krause

发明人： Wolfgang Rollinger ,  Johann Karl ,  Norbert Wild ,  Herbert Andres ,  Peter Heiss ,  Ursula Garczarek ,  Andrea Geistanger ,  Friedemann Krause

IPC分类号： G01N33/573

CPC分类号： G01N33/57419 ,  G01N2333/8146

摘要： The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein TIMP-1 (tissue inhibitor of metalloproteinase 1) as a marker molecule in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual, the method involving measuring TIMP-1 in the sample. Measurement of TIMP-1 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

摘要翻译： 本发明涉及结肠直肠癌的诊断。 它公开了使用蛋白质TIMP-1（金属蛋白酶1的组织抑制剂）作为结直肠癌诊断中的标记分子。 本发明涉及从个体得到的粪便样品中诊断结肠直肠癌的方法，该方法涉及在样品中测量TIMP-1。 TIMP-1的测定可以例如用于结肠直肠癌的早期检测或诊断。

公开(公告)号：US20090075312A1

公开(公告)日：2009-03-19

申请号：US12141278

申请日：2008-06-18

申请人： Norbert Wild ,  Veit Peter Grunert ,  Johann Karl ,  Jarema Peter Kochan ,  Peter Stegmueller ,  Michael Tacke

发明人： Norbert Wild ,  Veit Peter Grunert ,  Johann Karl ,  Jarema Peter Kochan ,  Peter Stegmueller ,  Michael Tacke

IPC分类号： C12Q1/48 ,  G01N33/00

CPC分类号： G01N33/57419 ,  G01N2333/52 ,  G01N2333/70503

摘要： The present invention relates to a method aiding in the assessment of colorectal cancer (=CRC). It discloses the use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer. Furthermore, it especially relates to a method for assessing colorectal cancer from a liquid sample, derived from an individual by measuring at least the markers osteopontin and carcinoembryonic antigen in said sample. The marker combination comprising osteopontin and carcinoembryonic antigen can, e.g., be used in the early detection of colorectal cancer or in the surveillance of patients who undergo therapy, e.g., surgery.

摘要翻译： 本发明涉及一种协助评估结肠直肠癌（= CRC）的方法。 它公开了在评估结肠直肠癌中使用包含骨桥蛋白和癌胚抗原的标记物组合。 此外，它特别涉及通过至少测量所述样品中的骨桥蛋白和癌胚抗原来评估来自个体的来自液体样品的结肠直肠癌的方法。 包括骨桥蛋白和癌胚抗原的标记物组合可以例如用于结肠直肠癌的早期检测或用于进行例如手术治疗的患者的监视。

公开(公告)号：US20120157335A1

公开(公告)日：2012-06-21

申请号：US13351801

申请日：2012-01-17

申请人： Norbert Wild ,  Marie-Luise Hagmann ,  Johann Karl ,  Julia Riedlinger ,  Markus Roessler ,  Michael Tacke

发明人： Norbert Wild ,  Marie-Luise Hagmann ,  Johann Karl ,  Julia Riedlinger ,  Markus Roessler ,  Michael Tacke

IPC分类号： C40B30/04 ,  G01N33/573 ,  C40B40/10 ,  G01N33/574 ,  C07K16/40

CPC分类号： G01N33/573 ,  G01N33/54306 ,  G01N33/57411 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/5743 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57442 ,  G01N33/57449 ,  G01N33/57488 ,  G01N2333/922 ,  G01N2800/52 ,  G01N2800/7028 ,  G16H50/30 ,  Y02A90/26

摘要： Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.

摘要翻译： 提供了帮助评估癌症的方法，包括使用Flap核酸内切酶-1蛋白（= FEN1）作为不同癌症类型的通用标记。 特别地，公开了从样品中得到的来自个体的液体样品中评估癌症的方法，其包括测量样品中的FEN1。 FEN1的测量可用于癌症的早期检测或用于手术切除肿瘤的患者的监测。

公开(公告)号：US20120028835A1

公开(公告)日：2012-02-02

申请号：US13272399

申请日：2011-10-13

申请人： Norbert Wild ,  Marie-Luise Hagmann ,  Johann Karl ,  Julia Kloeckner ,  Markus Roessler ,  Michael Tacke

发明人： Norbert Wild ,  Marie-Luise Hagmann ,  Johann Karl ,  Julia Kloeckner ,  Markus Roessler ,  Michael Tacke

IPC分类号： C40B30/04 ,  C40B40/10 ,  G01N33/574

CPC分类号： G01N33/57484

摘要： Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

摘要翻译： 披露了一种有助于评估癌症的方法。 它涉及使用Secernin-1蛋白（SCRN1）作为不同癌症类型的通用标记物。 更具体地公开了通过测量样品中的SCRN1来从源自个体的液体样品中评估癌症的方法。 SCRN1的测定可以例如用于癌症的早期检测或者进行手术的患者的监视。

公开(公告)号：US08058013B2

公开(公告)日：2011-11-15

申请号：US12412840

申请日：2009-03-27

申请人： Johann Karl ,  Veit Peter Grunert ,  Wolfgang Rollinger ,  Norbert Wild

发明人： Johann Karl ,  Veit Peter Grunert ,  Wolfgang Rollinger ,  Norbert Wild

IPC分类号： G01N33/53

CPC分类号： G01N33/564 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4737 ,  G01N2333/5412 ,  G01N2800/102

摘要： Disclosed is an in vitro method aiding in the further assessment of patients suffering from rheumatoid arthritis. The method especially is used in assessing whether an RA patient is at risk of disease progression. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of at least C-reactive protein (CRP) and interleukin-6 and correlating the concentrations determined to the likelihood of an underlying rapidly progressing form of RA. A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. The invention also relates to the use of a marker panel comprising C-reactive protein and interleukin-6 in the assessment of a patient with rheumatoid arthritis and it teaches a protein array device and kit, respectively, for performing the method of the invention.

摘要翻译： 公开了一种辅助进一步评估患有类风湿性关节炎患者的体外方法。 该方法特别用于评估RA患者是否处于疾病进展的风险。 该方法例如通过分析生物化学标记来实施，包括在样品中测量至少C反应蛋白（CRP）和白细胞介素-6的浓度，并将确定的浓度与RA的潜在快速进展形式的可能性相关联。 患有快速进展疾病的高风险患者可能是需要治疗的患者，或者如果已经需要治疗，需要进行不同的和更有效的治疗。 本发明还涉及在评估类风湿性关节炎患者中使用包含C-反应蛋白和白细胞介素-6的标记物片，并分别教导了用于实施本发明方法的蛋白质阵列装置和试剂盒。

公开(公告)号：US07846674B2

公开(公告)日：2010-12-07

申请号：US11472069

申请日：2006-06-21

申请人： Norbert Wild ,  Viet Peter Grunert ,  Johann Karl ,  Werner Zolg

发明人： Norbert Wild ,  Viet Peter Grunert ,  Johann Karl ,  Werner Zolg

IPC分类号： G01N33/53

CPC分类号： G01N33/564 ,  G01N33/6869

摘要： The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and interleukin 6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and interleukin 6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and interleukin 6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

摘要翻译： 本发明涉及一种协助评估类风湿性关节炎的方法。 该方法特别用于评估体外不存在或存在类风湿性关节炎。 该方法例如通过分析生物化学标记实施，包括在样品中测量抗CCP和白细胞介素6的浓度，并将确定的浓度与不存在或存在类风湿性关节炎相关联。 为了进一步改善本发明方法中RA的评估，可以与抗CCP和白细胞介素6一起测定一种或多种另外的标记物的水平，并与RA的不存在或存在相关。 本发明还涉及包含抗CCP和白介素6的标记物在诊断类风湿性关节炎中的用途，并且其教导了用于实施本发明方法的试剂盒。

公开(公告)号：US20140004544A1

公开(公告)日：2014-01-02

申请号：US14022289

申请日：2013-09-10

申请人： Johann Karl ,  Julia Riedlinger ,  Norbert Wild

发明人： Johann Karl ,  Julia Riedlinger ,  Norbert Wild

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/6884 ,  G01N2333/914 ,  G01N2333/916 ,  G01N2800/122 ,  G01N2800/60

摘要： An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein FEN1 in said sample in vitro.

摘要翻译： 一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。 本公开还涉及通过在体外测量所述样品中的蛋白质FEN1来评估来自个体的样品的COPD的方法。

公开(公告)号：US08062907B2

公开(公告)日：2011-11-22

申请号：US13024543

申请日：2011-02-10

申请人： Norbert Wild ,  Veit Peter Grunert ,  Johann Karl ,  Werner Zolg

发明人： Norbert Wild ,  Veit Peter Grunert ,  Johann Karl ,  Werner Zolg

IPC分类号： G01N33/564 ,  C07K14/47 ,  C07K16/18

CPC分类号： G01N33/564 ,  G01N2800/102 ,  G01N2800/24 ,  G01N2800/52

摘要： Disclosed is a method for assessing a severity of rheumatoid arthritis. The method involves measuring in a patient sample a concentration of anti-cyclic citrullinated peptides (anti-CCP) and serum amyloid A, combining the concentrations determined to obtain a combined value, and comparing the combined value to a cut-off value established from a reference population. In another method, a marker selected from the group consisting of C-reactive protein (CRP), interleukin 6 (IL-6), S100 protein, osteopontin, rheumatoid factor (RF), matrix metalloprotease 1 (MMP-1), matrix metalloprotease 3 (MMP-3), hyaluronic acid, and soluble CD14 (sCD14) may also be determined along with the anti-CCP and serum amyloid A.

摘要翻译： 公开了一种评估类风湿性关节炎严重程度的方法。 该方法包括在患者样品中测量抗环瓜氨酸肽（抗CCP）和血清淀粉样蛋白A的浓度，将确定的浓度组合以获得组合值，并将组合值与从 参考人口。 在另一种方法中，选自C反应蛋白（CRP），白介素6（IL-6），S100蛋白，骨桥蛋白，类风湿因子（RF），基质金属蛋白酶1（MMP-1），基质金属蛋白酶 3（MMP-3），透明质酸和可溶性CD14（sCD14）也可以与抗CCP和血清淀粉样蛋白A一起测定。